D
David C. Dale
Researcher at University of Washington
Publications - 419
Citations - 26111
David C. Dale is an academic researcher from University of Washington. The author has contributed to research in topics: Neutropenia & Congenital Neutropenia. The author has an hindex of 85, co-authored 406 publications receiving 24613 citations. Previous affiliations of David C. Dale include National Institutes of Health & Fred Hutchinson Cancer Research Center.
Papers
More filters
Book ChapterDOI
Cyclic and Chronic Neutropenia
David C. Dale,Karl Welte +1 more
TL;DR: This chapter focuses on cyclic and congenital neutropenia, two very interesting and rare hematological conditions causing severe chronic neutropania and treatment with G-CSF.
Journal ArticleDOI
Lithium therapy of canine cyclic hematopoiesis
William P. Hammond,David C. Dale +1 more
TL;DR: The effects of lithium on the monocytes, platelets, and reticulocytes, as well as the neutrophils, suggest that lithium operates on basic regulatory mechanisms affecting the most primitive hematopoietic precursor cells.
Journal ArticleDOI
Studies of the Neutropenia of Acute Malaria
David C. Dale,Sheldon M. Wolff +1 more
TL;DR: These data provide a model for one mechanism of neutropenia in man: premature release of marrow granulocytes with a shift of the circulating cells into the marginal pool.
Journal ArticleDOI
Aging and marrow neutrophil reserves.
Gurkamal Chatta,Gurkamal Chatta,Gurkamal Chatta,Thomas H. Price,Thomas H. Price,Thomas H. Price,John R. Stratton,John R. Stratton,John R. Stratton,David C. Dale,David C. Dale,David C. Dale +11 more
TL;DR: Measurement of blood neutrophil (PMN) counts after the administration of hydrocortisone, granulocyte colony‐stimulating factor (G‐CSF) and epinephrine is presented.
Journal ArticleDOI
Renewed interest in granulocyte transfusion therapy
TL;DR: Neutropenia remains the principal factor limiting the use of chemotherapy for the treatment of cancer and a major cause of morbidity following bone marrow transplantation and the discovery and clinical development of the colony-stimulating factors have had a major impact to reduce the duration and severity of neutropania.